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Abstract 
The childhood motor neuron disease Spinal Muscular Atrophy (SMA) results from reduced 
expression of the Survival Motor Neuron (SMN) gene. Previous studies using in vitro model 
systems and lower organisms have suggested that low levels of Smn protein disrupt prenatal 
developmental processes in lower motor neurons, influencing neuronal outgrowth, axon 
branching and neuromuscular connectivity. The extent to which these developmental 
pathways contribute to selective vulnerability and pathology in the mammalian 
neuromuscular system in vivo remains unclear. Here, we have investigated pre-symptomatic 
development of neuromuscular connectivity in differentially vulnerable motor neuron 
populations in Smn-/-;SMN2 mice, a model of severe SMA. We show that reduced Smn 
levels have no detectable effect on morphological correlates of pre-symptomatic development 
in either vulnerable or stable motor units, indicating that abnormal pre-symptomatic 
developmental processes are unlikely to be a pre-requisite for subsequent pathological 
changes to occur in vivo. Microarray analyses of spinal cord from two different severe SMA 
mouse models demonstrated that only minimal changes in gene expression were present in 
pre-symptomatic mice. In stark contrast, microarray analysis of late-symptomatic spinal cord 
revealed widespread changes in gene expression, implicating extracellular matrix integrity, 
growth factor signalling and myelination pathways in SMA pathogenesis. Taken together, 
these data suggest that reduced Smn levels induce SMA pathology by instigating rapidly 
progressive neurodegenerative pathways in lower motor neurons around the time of disease 
onset rather than by modulating pre-symptomatic neurodevelopmental pathways. 
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Introduction 
Proximal autosomal recessive Spinal Muscular Atrophy (SMA) is a devastating childhood 
form of motor neuron disease, targeting lower motor neurons in the ventral horn of the spinal 
cord resulting in denervation and atrophy of muscles in the limbs and trunk [1]. It is the most 
common genetic cause of infant mortality in the human population, with an incidence of 
around 1:6,000-10,000 [1-3], and is caused by low levels of the survival motor neuron protein 
(Smn).  Smn is the ubiquitously-expressed protein product of a gene which exists in two near 
identical copies: SMN1 and SMN2 [3,4]. Reduced protein levels result from loss or disruption 
of the telomeric SMN gene (SMN1) but retention of the centromeric SMN gene (SMN2). The 
disease is characterised by an early disruption of neuromuscular connectivity, in the form of 
functional disruption and structural loss of neuromuscular junctions, which precedes a loss of 
lower motor neuron soma from the spinal cord and wasting of skeletal muscle [5-9]. Despite 
a clear understanding of the genetic cause of SMA, our understanding of the cellular and 
molecular mechanisms through which mutations in SMN lead to selective motor neuron loss 
and resultant clinical symptoms remains incomplete [1].  
 
Several studies have suggested that reduced Smn protein levels can have a significant 
influence on neurodevelopmental processes in lower motor neurons. For example, results 
from experiments using cultured neurospheres have shown that neuronal differentiation is 
inhibited in Smn-/-;SMN2 cells [10] and in vitro experiments utilising Smn-/-;SMN2 motor 
neurons reported reduced axon outgrowth [11,12].  Furthermore, axon outgrowth and 
pathfinding have been shown to be compromised in zebrafish and Xenopus models of SMA 
[13,14]. Although a failure to establish the neuromuscular system during embryogenesis 
appears unlikely to contribute to any developmental phenotype [15], these studies suggest 
that deficiencies in motor unit development (controlling factors such as motor unit branching, 
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size, pruning and function) may play a major role in conferring pre-symptomatic 
vulnerability upon lower motor neurons. Indeed, these studies have led to the suggestion that 
SMA may be caused by incorrect development of the neuromuscular system, which would 
subsequently confer an intrinsic vulnerability upon lower motor neurons pre-
symptomatically, during pre-natal stages of growth and maturation. If this model of SMA 
pathogenesis turns out to be correct, then attempts to rescue the neuromuscular system post-
natally (e.g. by elevating levels of Smn protein using gene therapy or pharmaceutical 
approaches [16,17]) would likely have significant limitations. However, if pre-symptomatic 
developmental abnormalities are not a major feature of SMA, the neuromuscular system may 
remain intact until the postnatal onset of symptoms and therefore be more amenable to 
rescue. 
 
If prenatal developmental processes such as neuronal outgrowth and axon branching 
significantly contribute to SMA pathogenesis in mammals in vivo, we would expect to 
observe significant changes in the gross and/or fine morphology of neuromuscular 
connectivity, and/or changes in gene expression patterns in the spinal cord, preceding the 
onset of neuromuscular pathology in an established mouse model of severe SMA (Smn-/-
;SMN2 [18]). To directly test this, we have undertaken a combined high-resolution analysis 
of neuromuscular morphology and gene expression in SMA mice at a pre-symptomatic age 
(postnatal day 1; P1). We have taken advantage of previous observations that different 
muscles/muscle regions are differentially vulnerable to pre-synaptic pathology [7] and 
examined pre-symptomatic development in neighbouring populations of lower motor neurons 
and neuromuscular junctions that are known to be subsequently vulnerable or resistant to 
pathological changes at later stages of disease progression (P5). We show that morphological 
perturbations in pre-symptomatic developmental pathways are neither present nor necessary 
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for subsequent lower motor neuron pathology to occur in SMA in vivo.  Parallel gene 
expression analyses of pre-symptomatic spinal cord from Smn-/-;SMN2 and slightly less 
severe Smn-/-;SMN2;delta7 [19] mice confirmed the absence of any disruption of 
developmental pathways, whereas equivalent microarray analyses at late-symptomatic ages 
indicated an extensive breakdown in neuronal integrity, implicating extracellular matrix 
stability, myelination and growth factor signalling pathways in disease pathogenesis. 
 
Results  
No detectable morphological abnormalities in pre-symptomatic development in either 
vulnerable or non-vulnerable motor units in severe SMA mice. 
To establish whether pre-symptomatic developmental abnormalities are a significant feature 
of SMA pathogenesis in vivo we initially examined morphological correlates of lower motor 
neuron connectivity in the Smn-/-;SMN2 mouse model of severe SMA at pre-symptomatic 
ages (post-natal day 1; P1 [18,7]). We have previously shown that, in our hands, Smn-/-
;SMN2 mice (as well as less severe Smn-/-;SMN2;delta7 mice; see below) are 
indistinguishable from their wild-type littermates at P1 and that pathological changes in the 
neuromuscular system are almost entirely absent [7; Baumer et al., manuscript under review].  
 
The homogeneously fast-twitch Levator Auris Longus (LAL) muscle provided us with an 
excellent model system with which to study selectively vulnerable populations of lower 
motor neurons in these mice, allowing a direct comparison of neighbouring populations of 
differentially-affected motor units whilst eliminating variables such as nerve stump length, 
muscle fibre type and muscle function [7]. Whole mount LAL muscles from P1 Smn-/-
;SMN2 and litter-mate control mice (Smn+/+;SMN2,) were labelled with antibodies against 
150kDa neurofilament to reveal axonal and synaptic morphology and rhodamine-conjugated 
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α-bungarotoxin to label post-synaptic acetylcholine receptors at the neuromuscular junction 
[7,20].   
 
Confocal micrograph montages of the whole LAL muscle (incorporating both caudal and 
rostral bands) allowed analysis of the gross muscle innervation pattern in pre-symptomatic P1 
mice (Figure 1).  No differences were observed between the gross innervation patterns of 
either the rostral (non-vulnerable motor units) or caudal (vulnerable motor units) bands of the 
LAL in Smn-/-;SMN2 and litter-mate control mice (N=8 control muscles; N=14 Smn-/-
;SMN2 muscles). Endplates were clustered into distinct and highly characteristic innervation 
bands in all muscles examined: termed C1 and C2 in the caudal band and R1-5 in the rostral 
band (Figure 1A). Axons entered adjacent to region C1 in all muscles examined and, 
although there was a small amount of normal biological variability within genotypes, gross 
intra-muscular nerve branching patterns were not altered in Smn-/-;SMN2 muscles (Figure 
1D). Quantification of the numbers of neuromuscular synapses in regions C2 and R3-5 
(selected because these areas were least likely to suffer damage during muscle dissection) 
revealed no differences between Smn-/-;SMN2 and control mice (Figure 1E,F).  This was in 
agreement with previous studies that reported no obvious discrepancy in the initial embryonic 
establishment of neuromuscular innervation patterns in SMA mice [15].  
 
Next, we considered the possibility that pre-symptomatic changes in lower motor neuron 
branching and motor unit size could conceivably lead to excessive demands being placed on 
individual lower motor neurons (e.g. functionally and/or energetically), thereby damaging the 
cell and pre-disposing it to subsequent degeneration.  Such defects in axonal pathfinding 
and/or branching would most likely manifest as alterations in the number of axons present in 
intramuscular nerve bundles.  We therefore quantified axon number in intramuscular nerve 
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bundles innervating regions C2 and R3 (two anatomically highly-consistent areas of the LAL 
muscle) in Smn-/-;SMN2 and control mice (Figure 2). Axons were only quantified in areas of 
the muscle where the complete endplate band could be seen in order to ensure that no other 
axon branches were entering the endplate band from a different nerve bundle. We did not 
observe sensory axons in any of the intramuscular axon bundles investigated (i.e. there were 
no axon profiles extending beyond the endplate band innervating sensory organs), meaning 
that all analyses only contained motor axons innervating the endplate region under 
investigation. Initial attempts to quantify the numbers of individual axons in intramuscular 
nerve bundles by undertaking analyses on raw confocal stacks and z-projections proved 
inconsistent and unreliable (Figure 2A&C). To achieve the necessary resolution required for 
accurate and robust analysis, confocal stacks were subjected to deconvolution analyses 
(Figure 2B&D). Quantification of axon numbers normalised to the number of endplates 
innervated revealed no difference in the numbers of axons innervating either C2 or R3/4 
regions of Smn-/-;SMN2 or control mice (Figure 2E).  
 
We next considered the possibility that subtle differences in the terminal branching of lower 
motor neurons (at the level of axonal inputs to individual neuromuscular junctions) could 
lead to hyper-innervation of muscle and a corresponding increase in motor unit size pre-
symptomatically in SMA. To address this possibility we counted the number of axon 
collaterals converging on individual post-synaptic endplates at neuromuscular junctions in 
both bands of the LAL muscle from Smn-/-;SMN2 and control mice. Note that at this age, 
neuromuscular junctions are normally poly-neuronally innervated, as the process of 
developmental synapse elimination is ongoing. No significant differences were found in the 
average number of inputs converging on endplates in either rostral or caudal bands between 
genotypes (Figure 3).  There was a small, but noticeable, trend towards an increased number 
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of inputs in Smn-/-;SMN2 mice compared to controls. However, as this small increase was 
present in both bands of the LAL, and equivalent levels were also observed in heterozygote 
controls (data not shown), these small differences are unlikely to contribute to subsequent 
selective neuromuscular vulnerability in the caudal band of the LAL.  
 
During our analyses of P1 muscles we observed numerous axon sprouts, in the form of 
neuronal projections extending from pre-synaptic motor nerve terminals (Figure 4), that have 
not been previously reported in the literature. These ‘developmental sprouts’ were 
consistently present in all bands of all muscles analysed, including both Smn-/-;SMN2 and 
litter-mate control mice. Developmental sprouts ranged in size from under 5µm to around 
250µm. To confirm that this was a natural phenomenon, and that it was not occurring due to 
the presence of the SMN2 transgene, we examined P1 muscles from wild-type CD1 mice (a 
completely unrelated genetic strain). Terminal developmental sprouts were present in CD1 
mice and were indistinguishable from those observed in Smn-/-;SMN2 and control mice at the 
same age (Supplementary Figure 1). Whilst this finding clearly warrants further investigation 
in future studies of normal neuromuscular development, it also serves to demonstrate that the 
‘developmental sprouts’ described here are not pathological and are distinct to previously 
described ‘denervation-induced sprouts’ which occur as a compensatory response to a loss of 
synaptic innervation at the neuromuscular junction [21]. However, neither the numbers of 
small (<150µm; see methods) nor larger ‘super sprouts’ (those >150µm in length) were 
modified in pre-symptomatic Smn-/-;SMN2 mice (Figure 4).  
 
Taken together, these data show that pre-symptomatic development of lower motor neuron 
connectivity, as far as can be observed using morphological techniques, occurs normally in 
both vulnerable and non-vulnerable motor units in severe SMA mice. 
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No detectable morphological abnormalities in post-synaptic maturation in Smn-/-;SMN2 
mice  
As lower motor neuron morphology and connectivity were unaffected in Smn-/-;SMN2 mice 
at pre-symptomatic stages, we next investigated whether changes in post-synaptic 
development at the neuromuscular junction were present and could account for subsequent 
vulnerability of motor units.  In agreement with previous studies, we have already established 
that the position and relative number of post-synaptic motor endplates were normal in both 
caudal and rostral bands of the LAL muscle in Smn-/-;SMN2 mice (Figure 1E).  
Quantification of individual endplate areas revealed a similar, normal distribution in Smn-/-
;SMN2 mice (Figure 5C).  As previous work has suggested that endplate maturation may 
have an impact upon lower motor vulnerability in SMA mice [22], we applied a scale to 
quantify and compare endplate maturation in Smn-/-;SMN2 and control mice (Figure 5A). 
Endplates were categorised as either ‘uniform’, where AChR receptors were evenly 
distributed within the endplate area, ‘folded’ where bright bands on the endplate had formed 
which were indicative of post synaptic fold formation (a sign of early maturation), or 
perforated, where holes in the AChR labelling were indicative of the endplate beginning to 
take on the adult ‘pretzel-like’ morphology [23].  Overall, there was no difference in the 
numbers or proportion of uniform, folded and perforated endplate morphologies between 
genotypes (Figure 5B).  However, we observed an increase in endplate maturation in the 
caudal band of the LAL in mice from both genotypes, as evidenced by an increase in the 
number of folded and perforated endplates.  This finding is consistent with motor units in the 
caudal band conforming to fast-synapsing ‘FaSyn’ characteristics, being developmentally 
more advanced than their delayed-synapsing ‘DeSyn’ neighbours [7,24] (note that FaSyn and 
DeSyn characteristics of motor units have no relevance to the fast-twitch / slow-twitch 
phenotype of motor units).   
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No detectable differences in pre-symptomatic development between differentially vulnerable 
fast-twitch and slow-twitch muscles 
Our finding that there were no detectable abnormalities in the development of lower motor 
neuron connectivity in both the rostral and caudal bands of the LAL implied that abnormal 
pre-symptomatic neuromuscular development does not contribute to the increased 
vulnerability of motor units in the caudal band of the LAL [7].  However, these analyses 
compared two bands of a homogenous fast-twitch muscle (albeit with different FaSyn/DeSyn 
characteristics). It therefore remained possible that abnormalities in pre-symptomatic 
development of lower motor neuron connectivity may contribute to the increased 
vulnerability of lower motor neurons innervating slow-twitch muscles compared to those 
innervating fast-twitch muscles [7].  To investigate this possibility, we increased the scope of 
our experiments to examine two muscles immediately deep to the LAL muscle: abductor 
auris longus (AAL) and auricularis superior (AS). The AAL is a predominantly fast-twitch 
muscle whilst the AS is predominantly slow-twitch (Figure 6). We chose these muscles for 
comparison because of their close proximity and function to one another (and the LAL) as 
well as their common innervation by the facial nerve (eliminating variables such as nerve 
stump length and body position, while still allowing whole mount analysis of the complete 
innervation pattern within a muscle). In late-symptomatic (P5) Smn-/-;SMN2 mice, there was 
approximately 25% denervation in the slow-twitch AS muscle while the fast-twitch AAL 
remained relatively unaffected (Figure 6). The increased vulnerability of slow-twitch muscles 
at late-symptomatic stages was therefore reflected in the increased pathology observed in the 
AS muscle.  
 
Comparable analyses of pre-symptomatic development to those detailed above for the LAL 
muscle revealed no significant differences in gross or fine neuromuscular development in the 
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AAL or AS muscles between Smn-/-;SMN2 and control mice (Figure 7). Interestingly, more 
advanced endplate maturation was observed in the less vulnerable AAL muscle compared to 
the AS muscle.   
 
Minimal changes in pre-symptomatic gene expression in mouse models of SMA.  
The experiments detailed in this study strongly suggest that lower motor neuron connectivity 
develops normally up until the onset of degenerative symptoms post-natally in severe SMA 
mice. Despite finding no morphological evidence for abnormal pre-symptomatic 
development of the neuromuscular system, it remained possible that developmental changes 
at the level of gene expression could impact on lower motor neuron vulnerability without 
modifying morphology.  To investigate this possibility, we undertook gene expression 
analyses in pre-symptomatic (P1) Smn-/-;SMN2 mouse spinal cord (N=4 mice per genotype, 
littermate matched). We used Affymetrix Mouse Exon ST arrays (see methods for protocol 
and details concerning experimental controls) to identify any statistically significant genes 
showing more than 1.5 fold changes in expression levels.  Out of 16,755 genes examined at 
P1, only 3 were significantly changed >1.5 fold (Table 1). The largest change observed was 
in expression levels of SMN1, providing an internal control for the sensitivity of the 
experiment.  The other two genes identified fell close to the margin of the 1.5 fold cut off (1.6 
fold down regulation and 1.7 fold up-regulation; Table 1), but neither are considered 
important for development of the neuromuscular system.  
 
To validate the virtual absence of gene expression changes in the Smn-/-;SMN2 microarray 
data, we repeated the microarray experiment using pre-symptomatic (P1) spinal cord tissue 
from the less severely affected Smn-/-;SMN2;delta7 mouse model of SMA (N=4 mice per 
genotype, littermate matched; [19]). These experiments revealed a similar lack of large-scale 
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expression changes for genes implicated in developmental pathways (Table 2). Taken 
together, these data suggest that reduced SMN expression levels exert no significant effect on 
pre-symptomatic gene expression in the spinal cord in vivo.   
 
Significant changes in gene expression were present in late-symptomatic Smn-/-;SMN2 mice  
As our morphological and gene expression analyses of SMA mice demonstrated that 
modifications in pre-symptomatic developmental pathways are unlikely to impact on 
subsequent SMA pathogenesis, we concluded that the breakdown of lower motor neurons is 
more likely due to the instigation of post-natal degenerative pathways.  In order to gain 
insight into the identity of cellular and molecular pathways underlying breakdown of the 
neuromuscular system in SMA, we repeated our microarray expression analysis using late-
symptomatic (P5) spinal cord from Smn-/-;SMN2 mice (N=3 mice per genotype, littermate 
matched).  Of the 16,755 individual genes investigated, 160 were significantly changed 
(P<0.05, unpaired t test) greater than 1.5 fold (Table 3 shows changes >2 fold; 
Supplementary Table 1 shows changes >1.5-1.99 fold). No multiple testing correction was 
applied to the data (e.g. Benjamini and Hochberg) as it was considered to be over-stringent 
for microarray data of this nature and sample size (i.e. no genes would be expected to pass 
the test). Array data were therefore validated at the protein level using quantitative western 
blotting  (see below). Both increases and decreases in gene expression levels were observed 
in Smn-/-;SMN2 mice, but none of the significantly increased genes were changed greater 
than 2-fold (therefore genes with increased expression can only to be found in Supplementary 
Table 1). The biggest single change was found for a gene in the myelination pathway, where 
we detected a significant 6.5 fold decrease in expression of myelin protein zero (P0). These 
results were in stark contrast to the P1 results (a 53 fold increase in the number of changed 
genes), underlining the minimal changes seen pre-symptomatically. A comparison of P1 and 
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P5 data also clearly underlined the scale and rapid progression of pathological changes that 
occur in the neuromuscular system in this severe model of SMA.  
 
Utilisation of GO-Elite MAPPFinder software to further investigate the potential function of 
genes shown to have modified expression levels identified 35 different cellular pathways 
which were modified in late-symptomatic (P5) Smn-/-;SMN2 spinal cord (Table 4). This in 
silico analysis highlighted changes in pathways relating to extracellular matrix integrity and 
growth factor signalling in SMA pathology.  
 
To validate the microarray findings and confirm that changes detected at the mRNA level in 
spinal cord led to corresponding changes at the protein level, we quantified protein 
expression levels of myelin protein zero (P0) in the spinal cord of late-symptomatic Smn-/-
;SMN2 mice and wild-type littermates at P5 using fluorescent western blotting (see methods). 
We observed a significant (~50%) reduction in P0 protein levels in Smn-/-;SMN2 mice, 
thereby validating the microarray dataset and confirming that the large reduction in P0 
mRNA detected on the microarray resulted in corresponding reductions in protein expression 
(Figure 8). 
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Discussion 
This study has generated two important findings. First, we have demonstrated that reduced 
Smn expression does not significantly modify pre-symptomatic lower motor neuron 
connectivity or gene expression in the spinal cord in vivo. Abnormal pre-symptomatic 
development of lower motor neuron connectivity is therefore unlikely to be a pre-requisite for 
subsequent pathology to occur in a mouse model of severe SMA. Second, we have shown 
that gene expression changes correlating with SMA pathology progress rapidly following the 
onset of symptoms, and that extracellular matrix integrity, growth factor signalling and/or 
myelination pathways may constitute viable therapeutic targets for stabilising lower motor 
neuron and spinal cord pathology in SMA. This study therefore highlights the importance of 
focusing on the role of Smn protein in maintaining the neuromuscular system once formed, 
rather than its role in regulating motor neuron outgrowth and axonogenesis, for understanding 
SMA pathogenesis. 
 
Our data suggest that the developmental effects of reduced Smn levels reported in vitro as 
well as in zebra fish and Xenopus models in vivo [10-14] are not mirrored in mammalian 
SMA models in vivo. Whilst it remains possible that Smn protein can influence 
developmental pathways including axon outgrowth and pathfinding in mammals under some 
experimental conditions, our data demonstrate that such changes are not sufficient to cause 
defects in the development of lower motor neuron connectivity in mouse models in vivo and 
are therefore not likely to be a major contributing factor to SMA pathogenesis in human 
patients.  As a result, efforts to understand the role of Smn protein in the triggering and 
progression of SMA pathology would likely be better served by focussing on events 
occurring during and around the onset of symptoms and motor neuron breakdown. Our data 
also suggest that modifier genes which influence disease severity in SMA, such as plastin 3 
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[25], are more likely to work through stabilising the neuromuscular system (e.g. by 
modifying actin dynamics) rather than by influencing pre-symptomatic developmental 
pathways such as axonogenesis [c.f. 25]. 
 
Although we could not detect alterations in pre-symptomatic development of lower motor 
neuron connectivity in vivo, we did observe some subtle differences between neuromuscular 
development of the rostral and caudal bands of the LAL, and between the AS and AAL 
muscles. The finding that endplate maturation was occurring faster in the caudal band of the 
LAL muscle is in agreement with our previous findings that motor units in this muscle band 
belong to the developmentally more advanced fast-synapsing (‘FaSyn’) subtype [7,24].  
Whilst this may indicate that increased maturation is linked to increased vulnerability, 
advanced endplate maturation was also seen in the relatively non-vulnerable AAL muscle 
compared to the less mature endplates in the vulnerable AS muscle.  These results indicate 
that the rate of endplate maturation is unlikely to directly impact upon motor unit 
vulnerability in SMA.  This is in contrast to recent published findings suggesting that 
increasing endplate maturation by exercise stabilises the neuromuscular junction and confers 
neuroprotection [22].  In light of our findings we would suggest revising the conclusions of 
Biondi and colleagues [22] to state that, while exercise can clearly be neuroprotective in 
SMA, endplate maturation is probably a by-product of the exercise regime and is not likely to 
have a direct effect on lower motor neuron vulnerability.  
 
One remarkable finding of the current study was that pre-symptomatic analyses of lower 
motor neuron morphology and gene expression revealed no detectable abnormalities in pre-
symptomatic development of lower motor neuron connectivity at P1, in a severe mouse 
model of SMA where the disease kills the animals by P6-P7. This highlights the rapid 
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progression of neuromuscular breakdown that occurs as a result of reduced SMN expression, 
but also gives great encouragement for the development of post-natally delivered treatments 
for SMA in human patients.  Had we found evidence for widespread disruption of pre-
symptomatic development of lower motor neurons, leading to subsequent changes in 
neuronal vulnerability, it would be difficult to envisage how this could be fully remedied by 
post-natal treatment options alone. By contrast, our results suggest the potential existence of a 
pre-symptomatic “therapeutic time window” in which the majority of lower motor neurons 
and neuromuscular synaptic connections remain phenotypicaly intact, extending into post-
natal days even in a mouse model of severe SMA where death occurs by P5-P6. This work 
therefore provides encouragement for current efforts to treat SMA post-natally, using 
strategies such as increasing SMN levels in the nervous system [16,26] or increasing full-
length splicing from the preserved SMN2 gene [17,27-33]. 
 
Our finding that pre-symptomatic developmental pathways are unlikely to contribute 
significantly to SMA pathogenesis suggests that a focus on cellular and molecular pathways 
active around the time of symptom onset will be required for a full understanding of the 
disease and for the identification of novel therapeutic targets. The late-symptomatic (P5) gene 
expression data presented in this study, supported by validation western blot experiments, 
provide some initial insights into these pathways. Whilst we cannot at this point dissect gene 
expression changes causing pathology from those resulting from pathological changes, nor 
directly measure and compare gene expression changes in vulnerable and stable populations 
of lower motor neurons, the data suggest that extracellular matrix integrity, growth factor 
signalling and myelination pathways are all significantly modified in SMA spinal cord. 
Moreover, the finding that gene expression changes are present in late symptomatic SMA 
spinal cord supports the prediction of altered gene expression based on SMN’s known role in 
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snRNP assembly as well as studies showing that reduced snRNP assembly in the spinal cord 
correlates with severity of SMA disease in mice [34-37].  
 
Whilst acknowledging the limitations of comparing gene expression on whole spinal cord 
extracts rather than isolated populations of lower motor neurons (which remains a technical 
challenge in neonatal mouse models of SMA), these microarray data represent the first 
attempt to understand pathways underlying pathological changes in the spinal cord in a 
mouse model of severe SMA. However, similar gene expression studies have previously been 
published using different mouse models of very mild forms of SMA [e.g. 38]. Although a 
comparison of the individual expression changes reported previously shows very little 
overlap with our experiments - as might be expected given the differing nature of 
pathological changes between the two models – previous studies highlighted similar changes 
in the expression of genes associated with the extracellular matrix [38]. It is conceivable that 
therapeutic strategies designed to preserve and support the extracellular matrix (often referred 
to as peri-neuronal nets in the nervous system) may help to sustain lower motor neuron form 
and function by influencing factors such as the maintenance of cellular relationships and 
adhesion, the control of synaptic plasticity and neurotransmitter receptor localisation, and the 
concentration of growth factors around neurons [39,40]. Similarly, the finding that genes 
associated with growth factor signalling are dys-regulated in late-symptomatic SMA spinal 
cord suggests that lower motor neurons may be breaking down as a result of abnormal trophic 
signalling. Trophic factors have long been considered as potential therapeutic agents for 
SMA [41], but a comprehensive analysis of the effects of different growth factors on SMA 
pathology has yet to be undertaken. Finally, our finding that key myelin proteins have 
reduced mRNA and protein levels in late-symptomatic SMA spinal cord may be of particular 
interest given that developmental downregulation of SMN in vivo coincides with the onset of 
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myelination [42]. Further investigations into the importance of growth factors, the 
extracellular matrix and myelination in SMA pathogenesis are therefore required. 
 
In summary, we have shown that abnormal pre-symptomatic development of lower motor 
neuron connectivity is not a pre-requisite for subsequent neuromuscular pathology in a mouse 
model of severe SMA. Future experiments examining neurodevelopmental aspects of the 
neuromuscular system in human tissue samples will now be required to confirm the relevance 
of our findings for human SMA pathogenesis. Future experiments will also be required to 
identify molecular mechanisms underlying the triggering of neuromuscular breakdown 
around the time of initial symptom onset, building on our identification of changes in 
pathways including extracellular matrix integrity, growth factor signalling and myelination. 
 
Materials & Methods  
Mice 
Smn+/-;SMN2 mice (Jackson labs strain no. 005024) were maintained as heterozygote 
breeding pairs under standard SPF conditions in animal care facilities in Edinburgh. All 
animal procedures and breeding were performed in accordance with Home Office and 
institutional guidelines. Litters produced from SMA colonies were retrospectively genotyped 
using standard PCR protocols (JAX® Mice Resources). Smn-/-;SMN2;delta7 mice were 
maintained as heterozygote breeding pairs under standard SPF conditions in animal care 
facilities in Oxford. Breeding and genotyping of these mice was performed as previously 
described [7]. Littermate mice (Smn+/+;SMN2) were used for controls throughout. 
 
Immunocytochemistry  
Neonatal (P1 for pre-symptomatic and P5 for late-symptomatic) Smn-/-;SMN2 mice and 
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control littermates were killed by chilling on ice and decapitation. The levator auris longus 
(LAL), adductor auris longus (AAL) and auricularis superior (AS) muscles from the back of 
the neck were dissected in oxygenated mammalian physiological saline (mM: NaCl 120, Kcl 
5, CaCl2 2, MgCl2 1, NaH2PO4 0.4, NaHCO3 23.8, D-glucose 5.6).  Muscles were exposed to 
α-bungarotoxin (BTX) conjugated to tetramethyl-rhodamine isothiocyanate (TRITC-α-
bungarotoxin; 5mg/ml, Molecular Probes) for 10 minutes and fixed in 0.1M PBS containing 
4% Paraformaldehyde (Electron microscopy sciences) for 15 minutes at room temperature. 
Muscles were blocked in 4% bovine serum albumin (BSA) and 1% TritonX in 0.1M PBS for 
30min before overnight incubation in primary antibodies raised against 150kDa 
neurofilament proteins (1:350 dilution; Chemicon International). After several rapid washes 
in 0.1M PBS, muscles were incubated in a 1:40 dilution of swine anti-rabbit secondary 
antibody conjugated to the fluorescent label FITC (Dako) for 4h. Muscles were whole-
mounted in Mowoil® (Calbiochem) on glass slides and cover-slipped before imaging.  
 
Imaging and analysis  
Muscle preparations were viewed using either a standard epi-fluorescence microscope 
equipped with a chilled CCD camera (40x objective; 0.8NA; Nikon IX71 microscope; 
Hammamatsu C4742-95), and/or a laser scanning confocal microscope (63x objective; 
1.4NA; Zeiss Axioskop). TRITC-α-BTX-labelled preparations were imaged using 543nm 
excitation and 590nm emission optics and FITC-labelled preparations utilised 488nm 
excitation and 520nm emission optics. For confocal microscopy, 488nm and 543nm laser 
lines were used for excitation and confocal Z-series were merged using ImageJ software. For 
deconvolution analysis, images were acquired using nyquist sampling and deconvolved using 
Huygens deconvolution software.   All images were assembled for publication using Adobe 
Photoshop software.  
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Morphological Quantification and Statistics 
All muscles used for quantification were imaged and reconstructed using Adobe Photoshop 
software so that the whole innervation pattern could be visualised, thus allowing orientation 
for subsequent analysis and elimination of any muscles which were damaged during 
dissection. All analyses were performed with the experimenter blind to genotype and muscle 
region.  The number of endplates per axon was quantified by evaluating axon number from 
deconvolved images.  Images were taken at approximately 100µm from the endplate area of 
interest to minimise variability introduced from axon branching occurring adjacent to sites of 
innervation. All muscles in which the complete area of innervation could not be seen, or 
additional axons branches were present, were excluded from further analysis.   Axon numbers 
were counted by visualisation in the X-Y plane and scanning up and down through the z-
series.  This was done at three pre-defined points per image with images re-blinded between 
each measurement. The average of each three counts was divided by the total number of 
endplates innervated by the axon bundle to give the average number of axons per endplate.   
The average number of inputs was evaluated by counting the number of pre-synaptic inputs 
contacting a given endplate. Any endplate in which the complexity of innervation made it 
difficult to define (e.g. overlying a major nerve branch) was excluded from further analysis.  
Quantification was performed on a minimum of 3 images per muscle (AS,AAL) or muscle 
band (LAL) totalling a minimum of 15 endplates per muscle/muscle band per mouse. To 
quantify sprouting, sprouts were catagorised as ‘small sprouts’ (those less than 150µm) or 
‘super sprouts’ (those exceeding 150µm).  Sprouts were defined as a neurofilament positive 
process that did not project to a cluster of AChR receptors.  Small sprouts were quantified by 
counting the number of sprouts in a given field of view expressed in relation to the number of 
endplates present.  A minimum of three fields of view were evaluated for each muscle 
(AAL/AS) or muscle band (LAL).  Super sprouts were quantified by counting the total 
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number of sprouts in a muscle region (C2 or R3-5 for LAL, whole muscle for AS/AAL) 
divided by the total number of endplates in the relevant region. Endplate maturation was 
evaluated by catagorising endplates as either uniform (even distribution of AChRs), folded 
(bright bands within the AChR region) or perforated (holes within the AChR staining) (see 
Figure 5).  Any endplate which was difficult to quantify due to orientation or proximity of 
other endplates was excluded from further analysis. For endplate area measurements, 
confocal images were imported into image J software and their outline was manually traced 
and the software used to calculate the area. Again, any endplate which difficult to measure 
due to orientation or proximity of other endplates was excluded.  All data were collected and 
analysed using GraphPad Prism software. 
 
RNA Isolation and Microarray 
Whole spinal cords were removed and RNA was extracted using an RNEasy micro kit 
(Qiagen). Any genomic DNA was removed using an on column digest. The quality and 
integrity of RNA was assessed on a BioAnalyzer; all samples had a RNA Integrity Number 
(RIN) ≥9 (Agilent Laboratories, US). 1µg starting RNA was ribosome depleted using the 
Ribominus Human/Mouse Transcriptome Isolation kit (Invitrogen). Labelled sense ssDNA 
for hybridization was generated with the Affymetrix GeneChip WT sense target labelling and 
control reagents kit (Affymetrix, UK) according to the manufacturer’s instructions.  Sense 
ssDNA was fragmented and the distribution of fragment lengths was measured on the 
BioAnalyser.  The fragmented ssDNA was labelled and hybridized to the Affymetrix 
GeneChip Mouse Exon 1.0 ST Array (Affymetrix). Chips were processed on an Affymetrix 
GeneChip Fluidics Station 450 and Scanner 3000. The core genes on the arrays were RMA 
normalized in GeneSpring GX 9 and differentially expressed genes were identified using an 
unpaired t-test with a p-value cut off of ≤0.05 and a fold change difference between SMA and 
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wild-type samples of ≥1.5. No multiple testing correction was applied to the data. The genes 
were sorted according to their gene ontology using GenMAPP’s GO-Elite. Only 
MAPPFinder ontologies with ≥3 genes changing and a permuted p-value ≤0.05 were 
selected. All array data has been submitted to MIAMExpress, where it will be publically 
available in ArrayExpress at The European Bioinformatics Institute 
(http://www.ebi.ac.uk/microarray-as/ae/). 
 
Quantitative fluorescent western blotting 
Quantitative western blots were performed as described previously [43,44], using antibodies 
against myelin protein P0 (Abcam, ab64685) and neuronal beta-tubulin (Abcam, ab24629) 
and a Typhoon laser scanner.  
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Figure Legends 
Figure 1: Normal muscle innervation and motor neuron branching patterns in pre-
symptomatic Smn-/-;SMN2 mice. A – Montaged photo-inverted fluorescent micrographs of 
a 150kDa neurofilament labelled LAL muscle reveal the highly consistent innervation pattern 
previously reported [7].  The muscle consists of two bands: caudal, defined by blue lines and 
rostral, defined by red lines. Two endplate regions exist within the caudal band (C1 and C2) 
and 5 endplate regions exist within the rostral band (R1-5).  B,C – Representative 
reconstructed LAL muscles from pre-symptomatic (P1) control (B) and Smn-/-;SMN2 (C) 
mice.  Note how the innervation patterns are indistinguishable between the two genotypes.  D 
– Representative tracings of motor neurons innervating the caudal band of the LAL muscle in 
control and Smn-/-;SMN2 mice showing similar gross morphology. E,F – Bar charts (mean ± 
SEM) showing no change in the number of endplates in control (+/+; black bars) compared to 
Smn-/-;SMN2 (-/-; white bars) LAL muscles in regions R3-5 (E) and C2 (F) (ns - non-
significant by an unpaired students t-test.  n=7/8 per rostral/caudal band control, n=14/12 per 
rostral/caudal band Smn-/-;SMN2). Scale bars = 500µm. 
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Figure 2: Quantification of intramuscular axon numbers revealed no change in Smn-/-
;SMN2 mice.   A,B  - Confocal micrographs showing x/y projections of an axon bundle 
which represent the raw image (A) or the same image which has undergone deconvolution 
processing (B).  C,D - Visualisation of the same images in z projection demonstrates the 
increased image clarity in deconvolved (D) images compared to raw images (C). For 
example, individual axon profiles easily identifiable in D (red arrows) are not easily 
distinguished in C (red arrows).  E – Bar chart (mean ± SEM) revealing no significant change 
in the average number of endplates per axon in either region R3 or C2 of the LAL muscle 
between P1 Smn-/-;SMN2 and control littermate mice (n=6/4 per rostral/caudal band control, 
n=9/10 per rostral/caudal band Smn-/-;SMN2; ns - non-significant by Kruskal-Wallis test 
with Dunn’s post-hoc test).  Scale bar = 15µm. 
 
Figure 3: No significant change in the number of axonal inputs per endplate in Smn-/-
;SMN2 mice. A – Representative confocal micrograph of an LAL muscle from a P1 control 
littermate mouse, labelled with antibodies against 150kDa neurofilaments (green, upper left 
panel) and TRITC-α-bungarotoxin (red, lower left panel), illustrating the type of images used 
for the quantification of axonal inputs. Note the complexity of innervation patterns at this age 
and high degree of poly-neuronal innervation (i.e. multiple axons converging on a single 
motor endplate). B – Bar chart (mean ± SEM) showing no significant difference in the 
number of inputs per endplate in either the rostral or caudal band of the LAL muscle between 
P1 Smn-/-;SMN2 and control littermate mice (n=6/6 per rostral/caudal band control, n=8/8 
per rostral/caudal band Smn-/-;SMN2; ns -  non-significant by ANOVA).  Scale bar = 30µm. 
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Figure 4:  Axonal sprouts were present in both rostral and caudal bands of the LAL 
muscle at P1, but were unchanged in Smn-/-;SMN2 mice. A – Representative confocal 
micrographs from an immunohistochemically labelled LAL muscle preparations (green = 
150kDa neurofilaments; red = post-synaptic acetylcholine receptors labelled with TRITC-α-
bungarotoxin) showing the presence of small sprouts projecting from nerve terminals in both 
rostral (left) and caudal (right) muscle bands in both control (upper panels) and Smn-/-;SMN2 
(lower panels) mice at P1.  Sprouts were identified as neurofilament positive projections not 
contacting AChR clusters (see white arrowheads).  B – Bar chart (mean ± SEM) showing no 
change in the number of small sprouts per endplate in Smn-/-;SMN2 mice compared to 
controls (n=6/6 per rostral/caudal band control, n=8/8 per rostral/caudal band Smn-/-;SMN2; 
ns -  non-significant by ANOVA).  Scale bar = 40µm. C – Representative confocal 
micrograph reconstructions showing large super sprouts (axonal projections exceeding 
150um in length; white arrowheads) in rostral band regions R3-5 and caudal band region C2 
from immunohistochemically labelled LAL muscle preparations from P1 control (+/+) and 
Smn-/-;SMN2 (-/-) mice (green = 150kDa neurofilaments; red = post-synaptic acetylcholine 
receptors labelled with TRITC-α-bungarotoxin).  D – Bar chart (mean ± SEM) showing no 
significant difference in the numbers of super sprouts (normalised to the number of 
endplates) present in regions R3-5 and C2 of the LAL muscle of Smn-/-;SMN2 mice (n=8/8 
per rostral/caudal band control, n=15/14 per rostral/caudal band Smn-/-;SMN2; ns -  non-
significant by ANOVA).  Scale bars = 20µm. 
 
Figure 5: AChR receptor clustering and maturation were normal in P1 Smn-/-;SMN2 
mice.  A – Representative micrographs of AChRs labelled with TRITC-α-bungarotoxin 
showing parameters for classification of endplates as either uniform (left; even distribution of 
AChR receptors), folded (middle; bright bands appear representing formation of post 
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synaptic folds), or perforated (right; holes appear in AChR receptor clustering). B – Bar chart 
(mean ± SEM) showing the percentage of endplates in regions R3-5 and C2 of the LAL 
muscle from Smn-/-;SMN2 (-/-) and control (+/+) mice which conform to a uniform (black 
bars), folded (grey bars) or perforated (white bars) morphology.  No significant difference 
was observed between Smn-/-;SMN2 and control animals (P>0.05; Kruskal-Wallis test) 
although there was an increase in endplate maturation in the caudal band compared to the 
rostral band, as evidenced by an increase in perforated endplates with a corresponding 
decrease in uniform endplates in both genotypes (n=8/8 per rostral/caudal band control, 
n=15/14 per rostral/caudal band Smn-/-;SMN2).  C – Box and whisker plot showing no 
change in the distribution of endplate areas between rostral and caudal bands of the LAL 
muscle from Smn-/-;SMN2 and control mice (P>0.05 for all comparisons, Kruskal-Wallis 
test; n=8/8 per rostral/caudal band control, n=15/14 per rostral/caudal band Smn-/-;SMN2). 
 
Figure 6: Selective vulnerability of motor units in the slow twitch auricularis superior 
(AS) muscle compared to the fast twitch abductor auris longus (AAL) muscle in late-
symptomatic (P5) Smn-/-;SMN2 mice.  A – Representative micrographs of AAL and AS 
muscles sectioned coronally and stained with antibodies against either slow myosin (upper 
panel) or fast myosin (lower panel). Note how the AAL muscle is composed of 
predominantly fast twitch fibres while the AS muscle is composed of predominantly slow 
twitch fibres (albeit with fast-twitch fibres also present).  B – Confocal micrographs from 
immunohistochemically labelled AAL (left) and AS (right) muscles from P5 Smn-/-;SMN2 
mice (green = 150kDa neurofilaments; red = post-synaptic acetylcholine receptors labelled 
with TRITC-α-bungarotoxin) showing large numbers of denervated endplates in the AS 
muscles while the AAL muscle remained relatively spared.  C – Bar chart (mean ± SEM) 
showing the percentage of fully occupied endplates from P5 Smn-/-;SMN2 AAL and AS 
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muscles.   Note that only 75% of endplates in the AS muscle remain fully innervated at this 
stage of the disease whereas nearly 100% of connections remained in the AAL muscle (* 
P<0.01 Mann Whitney test; n = 6/6 per AAL/AS muscle and genotype). Scale bar = 100µm 
(A), 15µm (B). 
 
Figure 7: Abnormal pre-symptomatic development does not account for the selective 
vulnerability of motor units in slow twitch muscles. A,B – Montaged photo-inverted 
fluorescent micrograph reconstructions of neurofilament labelled AAL (left) and AS (right) 
muscles from control (A) and Smn-/-;SMN2 (B) mice indicated that the highly consistent 
innervation patterns formed normally, even for motor neurons innervating the pathologically-
vulnerable slow-twitch AS muscle.  C,D - Bar charts (mean ± SEM) showing no significant 
difference in the number of endplates between control (+/+; black bars) and Smn-/-;SMN2 (-/-
; white bars) AAL or AS muscles.  E - Bar chart showing the percentage of endplates in AAL 
and AS muscles from Smn-/-;SMN2 (-/-) and control (+/+) mice which conform to a uniform 
(black bars), folded (grey bars) or perforated (white bars) morphology.  No significant 
difference was seen between Smn-/-;SMN2 and control animals, although there was an 
increase in endplate maturation in the AAL compared to AS muscle in both genotypes.  F – 
Box and whisker plot showing no change in the distribution of endplate areas between 
control (+/+; black bars) and Smn-/-;SMN2 (-/-; white bars) mice in either AAL or AS 
muscles (P>0.05 for all comparisons, Kruskal-Wallis test). G – Representative confocal 
micrographs from immunohistochemically labelled AAL/AS muscle preparations from P1 
control and Smn-/-;SMN2 mice (green = 150kDa neurofilaments; red = post-synaptic 
acetylcholine receptors labelled with TRITC-α-bungarotoxin) showing the presence of small 
sprouts projecting from nerve terminals in both AAL (left) and AS (right) muscles in all 
muscles examined.  H – Bar chart showing no significant difference in the number of small 
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sprouts per endplate in Smn-/-;SMN2 mice compared to littermate controls. I - Bar chart 
showing no significant difference in the number of super sprouts (normalised to the number 
of endplates) present in AAL and AS muscles between Smn-/-;SMN2 mice and control 
controls. J - Bar chart showing no significant difference between Smn-/-;SMN2 and control 
mice in the number of inputs per endplate in either the AAL or AS muscle.  K – Confocal 
micrograph reconstructions showing large super sprouts (axonal projections exceeding 
150µm in length) in immunohistochemically labelled AAL (left) and AS (right) muscle 
preparation from a P1 control mouse.  For all experiments n=8/6 per AAL/AS muscle 
control, n=8/9 per AAL/AS muscle Smn-/-;SMN2 (ns = non-significant by student t-test 
(A,B), Kruskal Wallis test (H,I) or ANOVA (J)). Scale bars = 500µm (A,B), 15µm (G), 
20µm (K). 
 
Figure 8: Reduction in protein expression levels of myelin protein P0 in late-
symptomatic SMA mouse spinal cord. A – Representative fluorescent western blots 
showing expression levels of myelin protein P0 and the loading control tubulin in wild-type 
(+/+) and Smn-/-;SMN2 (-/-) mouse spinal cord at post-natal day 5 (P5). B – Bar chart 
(mean±SEM) showing a significant reduction in myelin protein P0 expression levels in Smn-
/-;SMN2 (-/-) mouse spinal cord compared to wild-type (+/+) littermate mice at post-natal 
day 5 (***P<0.001; Unpaired t test; n=6 independent band measurements, N=3 mice). 
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Table 1: Gene expression changes >1.5 fold in pre-symptomatic (P1) Smn-/-;SMN2 mouse 
spinal cord compared to litter-mate controls (all genes significantly changed P<0.05; 
unpaired t-test). 
Gene Title Gene Symbol Entrez Gene ID Cytoband Fold change Regulation 
survival motor neuron 1 Smn1 20595 13qD1 2.7 down 
olfactory receptor 1288 Olfr1288 258395 2qE3 1.6 down 
developmental pluripotency associated 5A Dppa5a 434423 5qB1 1.7 up 
 
 
 
 
 
Table 2: Gene expression changes >1.5 fold in pre-symptomatic (P1) Smn-/-;SMN2;delta7 
mouse spinal cord compared to litter-mate controls (all genes significantly changed P<0.05; 
unpaired t-test). 
Gene Title Gene Symbol Fold change Regulation 
survival motor neuron 1 Smn1 3.4 down 
histone cluster 1, H1c Hist1h1c 1.8 up 
histone cluster 1, H2bc et al Hist1h2bc  1.8 up 
glycoprotein 49 A /// leukocyte immunoglobulin-like receptor, 
subfamily B, member 4 Gp49a /// Lilrb4 1.8 up 
olfactory receptor 1393 /// olfactory receptor 1392 Olfr1393 /// Olfr1392 1.6 down 
laminin, alpha 2 Lama2 1.6 up 
olfactory receptor 978 Olfr978 1.6 down 
kallikrein 1-related peptidase b21 et al Klk1b21  1.6 up 
polymerase (RNA) II (DNA directed) polypeptide H Polr2h 1.6 down 
ribosomal protein L14 /// RIKEN cDNA 5830454E08 gene Rpl14 /// 5830454E08Rik 1.5 down 
adrenomedullin Adm 1.5 down 
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Table 3: Gene expression changes >2 fold in late-symptomatic (P5) Smn-/-;SMN2 mouse 
spinal cord compared to litter-mate controls (all genes significantly changed P<0.05; 
unpaired t-test). 
Gene Title Gene Symbol Entrez Gene ID Cytoband Fold change Regulation 
myelin protein zero Mpz 17528 1qH3 6.5 down 
decorin Dcn 13179 10qC3 4.2 down 
microfibrillar-associated protein 4 Mfap4 76293 11qB2 3.8 down 
peripheral myelin protein 22 Pmp22 18858 11qB3 3.7 down 
osteoglycin Ogn 18295 13qA5 3.7 down 
periostin, osteoblast specific factor Postn 50706 3qC 3.6 down 
lumican Lum 17022 10qC3 3.5 down 
survival motor neuron 1 Smn1 20595 13qD1 3.5 down 
prostaglandin D2 synthase (brain) Ptgds 19215 2qA3 3.4 down 
collagen, type III, alpha 1 Col3a1 12825 1qC1.1 3.0 down 
collagen, type I, alpha 1 Col1a1 12842 11qD 2.9 down 
histocompatibility 2, et al H2-T22  15039  17qB1 2.7 down 
procollagen C-endopeptidase enhancer protein Pcolce 18542 5qG2 2.7 down 
ATP-binding cassette, sub-family A (ABC1), member 8a Abca8a 217258 11qE1 2.6 down 
thrombomodulin Thbd 21824 2qG3 2.5 down 
fibronectin 1 Fn1 14268 1qC3 2.5 down 
reticulocalbin 3, EF-hand calcium binding domain Rcn3 52377 7qB4 2.4 down 
dipeptidylpeptidase 4 Dpp4 13482 2qC1.3 2.3 down 
collagen, type I, alpha 2 Col1a2 12843 6qA1 2.3 down 
asporin Aspn 66695 13qA5 2.3 down 
immunoglobulin superfamily containing leucine-rich repeat Islr 26968 9qB 2.3 down 
dermatopontin Dpt 56429 1qH2.2 2.2 down 
solute carrier family 6 (neurotransmitter transporter, GABA), 
member 13 Slc6a13 14412 6qF1 2.2 down 
serine (or cysteine) peptidase inhibitor, clade G, member 1 Serping1 12258 2qD 2.2 down 
collagen, type XII, alpha 1 Col12a1 12816 9qE1 2.2 down 
gap junction protein, beta 2 Gjb2 14619 14qC3 2.2 down 
cadherin 5 Cdh5 12562 8qD3 2.2 down 
nidogen 2 Nid2 18074 14qA3 2.1 down 
AE binding protein 1 Aebp1 11568 11qA1 2.1 down 
Rho GTPase activating protein 19 Arhgap19 71085 19qC3 2.1 down 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 11 Slc7a11 26570 3qC 2.1 down 
histone cluster 1, H2bb Hist1h2bb 319178 13qA3.1 2.1 down 
solute carrier family 13 (sodium/sulfate symporters), member 4 Slc13a4 243755 6qB1 2.1 down 
vesicle-associated membrane protein 5 Vamp5 53620 6qC1 2.0 down 
vitronectin Vtn 22370 11qB5 2.0 down 
insulin-like growth factor 2 Igf2 16002 7qF5 2.0 down 
serine (or cysteine) peptidase inhibitor, clade D, member 1 Serpind1 15160 16qA3 2.0 down 
CD93 antigen Cd93 17064 2qG3 2.0 down 
laminin, alpha 2 Lama2 16773 10qA4 2.0 down 
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Table 4: Pathway analysis of late-symptomatic (P5) microarray results. 
GOID GO Name 
GO 
Type 
Number 
Changed 
Number 
Measured 
Number 
in GO 
Percent 
Changed 
Percent 
Present 
Z 
Score PermuteP 
Adjusted 
P 
≥3 genes changing & ≥50% genes changing p0.05 
43256 laminin complex C 3 5 7 60 71 12.7 0 0 
48407 platelet\-derived growth factor binding F 4 8 9 50 89 13.3 0 0 
           
≥3 genes changing and 20-49% genes changing p0.05 
42573 retinoic acid metabolic process P 4 10 11 40 91 11.8 0 0 
5605 basal lamina C 3 8 11 38 73 9.9 0 0 
46332 SMAD binding F 3 8 10 38 80 9.9 0 0 
6776 vitamin A metabolic process P 5 15 18 33 83 12.0 0 0 
5201 extracellular matrix structural constituent F 7 24 24 29 100 13.2 0 0 
1523 retinoid metabolic process P 3 11 14 27 79 8.3 0 0 
16101 diterpenoid metabolic process P 3 11 14 27 79 8.3 0 0 
30199 collagen fibril organization P 4 15 18 27 83 9.5 0 0 
6775 fat\-soluble vitamin metabolic process P 5 19 25 26 76 10.6 0 0 
6721 terpenoid metabolic process P 3 13 18 23 72 7.6 0 0 
5520 insulin\-like growth factor binding F 4 18 20 22 90 8.6 0 0 
5581 collagen C 4 18 19 22 95 8.6 0 0 
44420 extracellular matrix part C 13 59 71 22 83 15.5 0 0 
           
≥3 genes changing and 10-19% genes changing p0.05 
6022 aminoglycan metabolic process P 3 17 20 18 85 6.6 0 0 
30203 glycosaminoglycan metabolic process P 3 17 20 18 85 6.6 0 0 
19838 growth factor binding F 8 50 56 16 89 10.1 0 0 
5604 basement membrane C 7 44 54 16 81 9.5 0 0 
6817 phosphate transport P 11 70 80 16 88 11.8 0 0 
30198 
extracellular matrix organization and 
biogenesis P 7 49 59 14 83 8.9 0 0 
16620 
oxidoreductase activity\, acting on the 
aldehyde or oxo group of donors\, NAD or 
NADP as acceptor F 3 22 27 14 81 5.7 0.0005 0.0645 
5578 proteinaceous extracellular matrix C 31 234 267 13 88 18.0 0 0 
31012 extracellular matrix C 31 238 271 13 88 17.8 0 0 
1871 pattern binding F 10 79 93 13 85 9.9 0 0 
5539 glycosaminoglycan binding F 9 72 79 13 91 9.3 0 0 
8201 heparin binding F 7 56 62 13 90 8.2 0 0 
30247 polysaccharide binding F 9 76 86 12 88 9.0 0 0 
6720 isoprenoid metabolic process P 3 26 35 12 74 5.1 0.0035 0.2485 
6334 nucleosome assembly P 4 36 94 11 38 5.8 0.0005 0.0645 
7160 cell\-matrix adhesion P 8 75 85 11 88 8.0 0 0 
16903 
oxidoreductase activity\, acting on the 
aldehyde or oxo group of donors F 3 30 36 10 83 4.7 0.0015 0.147 
7422 peripheral nervous system development P 3 30 34 10 88 4.7 0.002 0.176 
1656 metanephros development P 4 41 51 10 80 5.3 0.0005 0.0645 
7596 blood coagulation P 5 52 59 10 88 5.9 0.0005 0.0645 
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FIGURE 1 
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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FIGURE 5 
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FIGURE 6 
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FIGURE 7 
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FIGURE 8 
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Abbreviations 
AChR – Acetylcholine receptor 
AAL – Abductor auris longus 
AS – Auricularis superior 
DeSyn – “Delayed Synapsing” neuromuscular junctions 
FaSyn – “Fast Synapsing” neuromuscular junctions 
LAL – Levator auris longus muscle 
SMA – Spinal muscular atrophy 
SMN – Survival of motor neuron gene 
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